Since the signaling lymphocytic activation molecule family member 7 (SLAMF7) gene is highly and consistently upregulated across all stages of myeloma [16], and is the target antigen (CS1) of the monoclonal antibody Elotuzumab [17], SLAMF7 was therefore chosen as it would potentially make a stable target for a tumor-specific promoter for an oncolytic Ad5. The gene discussed is SLAMF7; the disease is plasma cell myeloma.